PATENT COOPERATION TREATY

PCT

REC'D	30	JAN	2006
L			

WIPO PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 665009	FOR FURTHER AC	CTION	See Form PCT/IPEA/416		
International application No. PCT/JP2005/002194	International filing date (08.02.2005	day/month/year)	Priority date (day/month/year) 09.02.2004		
International Patent Classification (IPC) or national classification and IPC C07D237/14, C07D239/36, C07D241/18, A61K31/513, A61P29/00					
Applicant TANABE SEIYAKU CO., LTD. et al.					
This report is the international pre Authority under Article 35 and trar	liminary examination rensmitted to the applican	oort, established by this according to Article 36	International Preliminary Examining		
2. This REPORT consists of a total of	This REPORT consists of a total of 6 sheets, including this cover sheet.				
	This report is also accompanied by ANNEXES, comprising:				
a. \square sent to the applicant and to					
and/or sheets containi Administrative Instruct	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
beyond the disclosure Supplemental Box.	in the international app	lication as filed, as indic	ders contain an amendment that goes ated in item 4 of Box No. I and the		
b. (sent to the International B sequence listing and/or table Box Relating to Sequence	les related thereto. in c	omputer readable form (r of electronic carrier(s)) , containing a only, as indicated in the Supplemental nstructions).		
4. This report contains indications re	elating to the following it	ems:			
☐ Box No. I Basis of the opi	nion				
☐ Box No. II Priority					
⊠ Box No. III Non-establishm	ent of opinion with rega	rd to novelty, inventive	step and industrial applicability		
☐ Box No. IV Lack of unity of					
applicability; cit	ations and explanations	e) with regard to novelty supporting such statem	, inventive step or industrial nent		
☐ Box No. VI Certain docume		11 A1			
☐ Box No. VII Certain defects					
☐ Box No. VIII Certain observa	ations on the internation	ai application			
Date of submission of the demand		Date of completion of thi	s report		
07.03.2005		27.01.2006			
Name and mailing address of the international preliminary examining authority:		Authorized Officer	Bortiches Patoniany		
European Patent Office D-80298 Munich		Gregoire, A	year Pa		
Tel. +49 89 2399 - 0 Tx: 5236 Fax: +49 89 2399 - 4465	656 epmu d	Telephone No. +49 89 2	399-		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/JP2005/002194

	Box I	No. I Basis of th	e report		
1.	With filed,	regard to the langu unless otherwise i	uage, this report is based ndicated under this item.	on the international application in the	e language in which it was
	□ T v	This report is based which is the langua	d on translations from the g	original language into the following land for the purposes of:	anguage ,
	Ξ	□ publication of the	arch (under Rules 12.3 and e international application liminary examination (und	d 23.1(b)) (under Rule 12.4) ler Rules 55.2 and/or 55.3)	•
2.	have	been furnished to	ents* of the international a the receiving Office in res I" and are not annexed to	application, this report is based on (ponse to an invitation under Article : this report):	replacement sheets which 14 are referred to in this
	Desci	ription, Pages			
	1-48		as originally filed		
Claims, Numbers					
	1-20		as originally filed		
	□ a	a sequence listing	and/or any related table(s)	- see Supplemental Box Relating to	Sequence Listing
3.			nave resulted in the cance	llation of:	
		☐ the description,☐ the claims, Nos			
	Ω	\square the drawings, sl	neets/figs	e e	
		\square the sequence lis \square any table(s) rela	sting <i>(specify)</i> : ated to sequence listing <i>(s</i>	pecify):	
4.	had r Supp	not been made, sir olemental Box (Rul	ice they have been consid e 70.2(c)).	of) the amendments annexed to this lered to go beyond the disclosure as	s report and listed below filed, as indicated in the
	[[□ the description,□ the claims, Nos□ the drawings, s□ the sequence li	heets/figs	·	,
	[any table(s) rela	ated to sequence listing <i>(s</i>	pecify):	
	* _	Tf item 4 annl	ies, some or all of	these sheets may be marked	d "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/JP2005/002194

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
. Th	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:				
	the entire international application,				
\boxtimes	claims Nos. 17-19				
	because:				
\boxtimes	the said international application, or the said claims Nos. 17-19 relate to the following subject matter which does not require an international preliminary examination (specify):				
	see separate sheet				
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
	no international search report has been established for the said claims Nos.				
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
	the written form	☐ has not been furnished			
		☐ does not comply with the standard			
	the computer readable form	☐ has not been furnished			
		☐ does not comply with the standard			
	the tables related to the nucleon not comply with the technical r	tide and/or amino acid sequence listing, if in computer readable form only, do equirements provided for in Annex C-bis of the Administrative Instructions.			
	See separate sheet for further	details			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/JP2005/002194

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-20

No:

Inventive step (IS)

Yes: Claims

Claims

1-20

No: Claims

Industrial applicability (IA)

Yes: Claims

1-16, 20

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

 Certain published documents (Rule 70.10) and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 17-19 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1) Reference is made to the following documents:

D1: EP-A-1 323 709 (TORAY INDUSTRIES, INC) 2 July 2003 (2003-07-02)

D2: WO 00/00477 A (PFIZER PRODUCTS INC; DUPLANTIER, ALLEN, JACOB;

MILICI, ANTHONY, JOHN;) 6 January 2000 (2000-01-06)

2) Novelty (Art. 33 (1) and (2) PCT):

The compounds presently claimed differ from those of D1 e.g. in the presence of the aryl or heteroaryl ring A between the urea group and the central heterocyclic ring. They differ from those of D2 at least in the saturation level of the central heterocyclic ring. The present application thus complies with Art. 33(2) PCT.

3) Inventive Step (Art. 33 (1) and (3) PCT):

D1 is considered as the closest prior art since it discloses urea derivatives (see e.g. exemple 46) active as adhesive-molecule inhibitor and thus useful for therapies of inflammatory diseases.

The present compounds are structurally different from those of D1 in several part of the molecules, e.g the position of the terminal carboxyl group and the presence of an aryl or heteroaryl ring A between the urea group and the central heterocyclic ring.

The technical problem underlying the present application is the provision of further

PCT/JP2005/002194

compounds active as alpha-4 integrin mediated cell adhesion inhibitors useful in the treatment or prevention of inflammatory diseases.

In the light of the present prior art, the compounds of formula (I) can be considered as non-ovious solutions to the problem raised. Pages 14-15 of the description supports the biological activity of the examples so that an inventive step in the sense of Art. 33(2) PCT can be acknowledged for the present application.

4) Industrial Applicability (Art. 33(1) and (4) PCT):

For the assessment of the present claims 17-19 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item VI Certain document cited

Certain published document

Application No Patent No Publication date (day/month/year)

Filing date (day/month/year) Priority date (valid claim) (day/month/year)

WO2004/014859

19-02-2004

08-08-2003

10-08-2002